From the (1)Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China.
Department of Radiology, Huashan Hospital, Fudan University, Shanghai, China.
Endocr Pract. 2020 Dec;26(12):1458-1468. doi: 10.4158/EP-2020-0192.
To evaluate the endocrine abnormalities in intracranial germ cell tumors (iGCTs) treated with radio-therapy (RT), and to discuss the effects of RT on pituitary functions.
Seventy-seven patients diagnosed with iGCTs who had received RT and endocrine follow-up in Huashan Hospital between January 2010 and July 2017 were retrospectively analyzed, consisting of 49 germinomas and 28 NGGCTs. The median follow-up period was 50.0 months. Fifty-one patients had radiologically proved suprasellar/sellar lesions.
The male to female ratio was 62/15. The median endocrine follow-up period was 19 (4, 42) months. The median age at the last endocrine visit was 18 (16, 20) years old. The 5-year overall and recurrence-free survival were both 98.7%. The overall prevalence of central adrenal insufficiency (CAI), central hypothyroidism (CHT), central hypogonadism (CHG), hyperprolactinemia, and central diabetes insipidus (CDI) was 57.3%, 56%, 56.6%, 35.3%, and 52.1%, respectively, after RT. Patients having suprasellar/sellar lesions showed significantly higher post-therapeutic prevalence of hypopituitarism than those who didn't. Compared to that before RT, CAI, CHT, and CHG weren't significantly improved while the levels of prolactin and the prevalence of CDI declined significantly (P =.03 and.001). The radiation doses to pituitary and hypothalamus between those with and without CAI, CHT, and CHG weren't significantly different.
The prevalence of hypopituitarism was high in iGCTs, especially in those with suprasellar/sellar involvement. The levels of prolactin and the prevalence of CDI declined significantly after RT. The hypopituitarism in iGCTs was mainly induced by tumor effects, and RT showed no additional damage to pituitary functions in our study.
AFP = alpha-fetoprotein; CAI = central adrenal insufficiency; CDI = central diabetes insipidus; CHG = central hypogonadism; CHT = central hypothyroidism; CT = computed tomography; DA = dopamine; GH = growth hormone; βHCG = beta-human chorionic gonadotropin; HPA = hypothalamus-pituitary-adrenal; HPG = hypothalamus-pituitary-gonadal; HPL = hyperprolactinemia; HPT = hypothalamus-pituitary-thyroid; iGCT = intracranial germ cell tumor; IGF-1 = insulin-like growth factor 1; NGGCT = nongerminomatous germ cell tumors; OS = overall survival; PFS = progression-free survival; PRL = hypothalamus-pituitary-prolactin; RT = radiotherapy.
评估接受放疗(RT)治疗的颅内生殖细胞肿瘤(iGCT)的内分泌异常,并探讨 RT 对垂体功能的影响。
回顾性分析 2010 年 1 月至 2017 年 7 月在华山医院接受 RT 及内分泌随访的 77 例 iGCT 患者,包括 49 例生殖细胞瘤和 28 例非生殖细胞瘤性生殖细胞肿瘤(NGGCT)。中位随访时间为 50.0 个月。51 例患者有影像学证实的鞍上/鞍内病变。
男女比例为 62/15。内分泌中位随访时间为 19(4,42)个月。末次内分泌随访时的中位年龄为 18(16,20)岁。5 年总生存率和无复发生存率均为 98.7%。放疗后,中枢性肾上腺功能不全(CAI)、中枢性甲状腺功能减退(CHT)、中枢性性腺功能减退(CHG)、高泌乳素血症和中枢性尿崩症(CDI)的总体发生率分别为 57.3%、56%、56.6%、35.3%和 52.1%。有鞍上/鞍内病变的患者,治疗后垂体功能减退的发生率明显高于无鞍上/鞍内病变的患者。与放疗前相比,CAI、CHT 和 CHG 无明显改善,而泌乳素水平和 CDI 的发生率显著下降(P =.03 和.001)。有和无 CAI、CHT 和 CHG 的患者垂体和下丘脑的放疗剂量无显著差异。
颅内生殖细胞肿瘤患者的垂体功能减退发生率较高,尤其是伴有鞍上/鞍内病变的患者。放疗后,泌乳素水平和 CDI 的发生率显著下降。颅内生殖细胞肿瘤的垂体功能减退主要是由肿瘤引起的,在本研究中,RT 对垂体功能没有造成额外的损害。